The Multiple Myeloma Therapy Market is expanding steadily as the healthcare industry invests in more effective and personalized approaches to treating multiple myeloma. According to WiseGuyReports, the market reached approximately USD 37.4 billion in 2024 and is estimated at USD 39.8 billion in 2025, with revenue projected to reach USD 75.0 billion by 2035, reflecting a 6.5% CAGR from 2026 to 2035.

The industry is segmented into chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, with targeted and immune-based approaches receiving significant attention. Targeted therapy was valued at approximately USD 15.0 billion in 2024 and is forecast to reach USD 30.0 billion by 2035. These therapies are supported by advances in molecular research and the development of medicines designed to address specific characteristics of multiple myeloma.

Treatment requirements differ throughout the course of the disease, creating demand across initial treatment, relapsed treatment, and maintenance therapy. The market also covers oral, intravenous, and subcutaneous administration routes and adult, geriatric, and pediatric patient groups. Growing investment in research and the development of new treatment combinations are helping expand therapeutic choices.

From a regional perspective, North America has the largest market value, estimated at USD 17.2 billion in 2024 and projected to reach USD 32.5 billion by 2035. Europe remains an important market, while Asia Pacific is expected to experience continued development as healthcare infrastructure improves and access to advanced therapies expands.

Future opportunities will come from advances in personalized medicine, immunotherapy, CAR-T cell therapy, monoclonal antibodies, and BCMA-targeted treatments. Companies are also investing in collaborations and manufacturing expansion to support next-generation therapies. With multiple myeloma treatment becoming increasingly specialized and technology-driven, continued research and innovation should remain central to market development over the coming decade.